FRAZIER LIFESCIENCES ACQUISITION CORPORATION

Press Releases Frazier Lifesciences Acquisition Corporation

Equities

NAMS

NL00150012L7

Real-time Estimate Tradegate Other stock markets 10:48:03 29/05/2024 pm IST			5-day change	1st Jan Change
17.65 ^EUR	-9.07%		-0.36%	+73.77%

16/05	Transcript : NewAmsterdam Pharma Company N.V. - Special Call
15/05	TD Cowen Starts NewAmsterdam Pharma With Buy Rating	MT

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June	05:32pm	GL
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June	05:31pm	AQ
NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings	21/05	GL
NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings	21/05	AQ
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results	09/05	GL
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	04/05	GL
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	04/05	AQ
NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024	02/05	GL
NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024	02/05	AQ
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease	09/04	GL
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer	01/04	GL
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer	01/04	AQ
NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress	25/03	GL
NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD	12/03	GL
NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update	28/02	GL
NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update	28/02	AQ
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March	26/02	GL
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March	26/02	AQ
NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants	14/02	GL
NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants	14/02	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Frazier Lifesciences Acquisition Corporation

Equities

NAMS

NL00150012L7

Press Releases

Filters